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Cell Biochem Funct. 2017;35:269–277.Glucocorticoids are important for skeletal muscle energy metabolism, regulating glucose
utilization, insulin sensitivity, and muscle mass. Nicotinamide adenine dinucleotide phosphate‐
dependent 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1)‐mediated glucocorticoid acti-
vation in the sarcoplasmic reticulum (SR) is integral to mediating the detrimental effects of gluco-
corticoid excess in muscle. 11β‐Hydroxysteroid dehydrogenase type 1 activity requires
glucose‐6‐phosphate transporter (G6PT)‐mediated G6P transport into the SR for its metabolism
by hexose‐6‐phosphate dehydrogenase (H6PDH) for NADPH generation. Here, we examine the
G6PT/H6PDH/11β‐HSD1 triad in differentiating myotubes and explore the consequences of
muscle‐specific knockout of 11β‐HSD1 and H6PDH. 11β‐Hydroxysteroid dehydrogenase type
1 expression and activity increase with myotube differentiation and in response to glucocorti-
coids. Hexose‐6‐phosphate dehydrogenase shows some elevation in expression with differentia-
tion and in response to glucocorticoid, while G6PT appears largely unresponsive to these
particular conditions. When examining 11β‐HSD1 muscle‐knockout mice, we were unable to
detect significant decrements in activity, despite using a well‐validated muscle‐specific Cre trans-
gene and confirming high‐level recombination of the floxed HSD11B1 allele. We propose that the
level of recombination at the HSD11B1 locus may be insufficient to negate basal 11β‐HSD1
activity for a protein with a long half‐life. Hexose‐6‐phosphate dehydrogenase was undetectable
in H6PDH muscle‐knockout mice, which display the myopathic phenotype seen in global KO
mice, validating the importance of SR NADPH generation. We envisage these data and models
finding utility when investigating the muscle‐specific functions of the 11β‐HSD1/G6PT/
H6PDH triad.
KEYWORDS
11β‐HSD1, G6PT, glucocorticoids, H6PDH, skeletal muscle1 | INTRODUCTION
Glucocorticoids fulfil important permissive and adaptive roles in the
regulation of skeletal muscle energy metabolism, impacting glucose
utilization, insulin sensitivity, amino acid, and lipid metabolism.1
Glucocorticoids can also influence muscle mass by regulating the bal-
ance between pathways affecting protein synthesis and protein degra-
dation, via modulation of amino acid transport, the anabolic actions of- - - - - - - - - - - - - - - - - - - - - - - - - - -
e Creative Commons Attribution Liinsulin and IGF1, and through the regulation of catabolic pathways
such as the ubiquitin proteasome system and E3 ubiquitin ligases
atrogin‐1 and muscle ring finger 1.2,3 Indeed, the importance of gluco-
corticoids to muscle is exemplified in patients with glucocorticoid
excess (Cushing's syndrome) who develop insulin resistance, muscle
weakness, and profound proximal myopathy.4
Glucocorticoid availability in muscle depends on circulating deliv-
ery and intracellular activation by 11β‐hydroxysteroid dehydrogenase- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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270 ZIELINSKA ET AL.type 1 (11β‐HSD1), which, in rodents, converts inactive 11‐
dehydrocorticosterone (11‐DHC) to corticosterone in a nicotinamide
adenine dinucleotide phosphate (NADPH)‐dependent reaction.5 11β‐
Hydroxysteroid dehydrogenase type 1 activity is dependent upon the
maintenance of an appropriate NADPH/NADP+ ratio at its site of
activity within the lumen of the sarcoplasmic reticulum (SR).6-8 To
achieve this, glucose‐6‐phosphate (G6P) is transported into the SR by
the G6P transporter (G6PT) and metabolized by the enzyme hexose‐
6‐phosphate dehydrogenase (H6PDH) to produce 6‐phosphogluconate
and NADPH.9 In H6PDH knockout (H6MKO) mice, a lack of adequate
NADPH generation and disruption of the H6PDH/11β‐HSD1 interac-
tion result in 11β‐HSD1 assuming activity to inactivate glucocorticoids
and increase their clearance.9-11
The role of 11β‐HSD1 in regulating muscle‐specific insulin signal-
ling and lipid utilization has been established.12,13 11β‐Hydroxysteroid
dehydrogenase type 1 expression and activity are elevated in type 2
diabetic muscles, and so 11β‐HSD1 inhibition may offer potential to
enhance insulin sensitivity.12 However, not all 11β‐HSD1 knockout
(HSD1KO) loss‐of‐function models have demonstrated protection
from metabolic disease and suggest that use of inhibitors will need to
be tailored to specific pathologies.14,15 Indeed, it has been shown that
11β‐HSD1KOmice are almost completely protected from the deleteri-
ous metabolic effects of glucocorticoid excess, and inhibition in this
scenario may be truly beneficial.3,12,13,16
To better evaluate the muscle‐specific contributions of 11β‐HSD1
and H6PDH to local and global glucocorticoid‐regulated metabolic
homeostasis, we have evaluated myotube expression and regulation
of the intraluminal enzymes 11β‐HSD1/H6PDH/G6PT and generated
skeletal muscle‐specific knockouts of 11β‐HSD1 (HSD1MKO) and
H6PDH (H6MKO). It is envisaged that these data will permit a more
thorough appreciation of their muscle‐specific functions in the context
of glucocorticoid excess and metabolic disease.2 | MATERIALS AND METHODS
Unless stated otherwise, all materials and reagents were purchased
from Sigma‐Aldrich, UK.2.1 | Cell culture
The mouse myoblast cell line, C2C12, is a well‐established model of
both skeletal muscle proliferation and differentiation. Proliferating
C2C12 myoblasts were cultured in Dulbecco's Modified Eagle Medium
(DMEM) supplemented with 10% fetal calf serum and seeded into 12‐
well tissue culture plates. Differentiation was initiated when cells
reached 60 to 70% confluence by replacing proliferation media with
DMEM supplemented with 5% horse serum and carried on for 8 days.
Prior to treatment, cells were incubated in serum‐free DMEM for
4 hours. Primary myoblasts were generated from isolated satellite cells
of the mouse extensor digitorum longus muscle. Primary myoblasts
were maintained in 12‐well tissue culture plates in 1 mL of DMEM
supplemented with 10% horse serum and 0.5% chick embryo extract.
Differentiation into myotubes was initiated by replacing proliferating
medium with DMEM supplemented with 2% horse serum and 0.5%chick embryo extract after myoblasts reached 60 to 70% confluence.
Differentiation medium was replaced every 48 hours. After 8 days of
differentiation, myoblasts fused to form multinucleated myotubes.
Cells were treated with dexamethasone (DEX; 1 μM), insulin (1 μM),
glucocorticoid receptor antagonist, Ru38486 (5 μM), and combination
of DEX with insulin and DEX with Ru38486. In experiments using
Ru38486, cells were pretreated with Ru38486 for 10 minutes before
adding DEX in DMEM media. Cell treatments were carried out for
24 hours.
2.2 | Animal generation and maintenance
All studies were conducted on male HSD1MKO, H6MKO, and wild‐
type (WT) mice group‐housed under controlled temperature
(21‐23°C) and light (12 h light, 12 h dark cycle; lights on at 0700 h).
The mice had ad libitum access to water and standard chow. Animal
procedures were approved under the British Home Office Animals
(Scientific Procedures) Act 1986 and through the Local Animal Ethics
Committee.
2.3 | Muscle‐specific 11β‐HSD1 knockout mouse
model
Previously, a conditional HSD11B1 allele was generated by flanking
exon 5 with LoxP sites, and from this, global 11β‐HSD1KO were
derived.17 To generate mice devoid of 11β‐HSD1 activity specifically
in skeletal muscle, we crossed homozygous floxed HSD11B1 mice on
a mixed C57BL/6J/129SvJ background with 3 different skeletal
muscle specific‐Cre transgenic mice: MEF2c‐Cre, ACTA1‐Cre, and
MCK‐Cre (Jackson Labs, all C57BL/6J). Each transgenic restricts Cre
expression to skeletal muscle tissue and to a lesser degree heart.
Genotyping PCR was carried out on ear clip DNA by using gene spe-
cific primers (5′‐3′) P1‐GGGAGCTTGCTTACAGCATC, P2‐CATTCT
CAAGGTAGATTGAACTCTG, and P3‐TCCATGCAATCAACTTCTCG.
P1 + P2 give a 138 bp product for a WT allele and a 172 bp product
for a conditional allele containing a 3′ LoxP site (Lox+/+). After a P2
binding site is removed and P1 + P3 are brought into proximity, they
produce a 279 bp KO band confirming successful Cre recombination
and exon 5 removal.
2.4 | H6PDH muscle‐knockout mouse model
The H6MKO first allele mice were purchased from the European Con-
ditional Mouse Mutagenesis Program (the European Mouse Mutant
Archive‐EMMA, Munich, Germany) that employs a KO first allele
strategy in which an SA‐βgeo‐pA reporter cassette (SA, splice accep-
tor; βgeo, β‐galactosidase/neomycin phosphotransferase fusion gene;
pA, bovine growth hormone polyadenylation sequence) flanked by
flippase recognition target sequence is inserted into the first intron
of H6PDH inactivating the gene. This global knockout was called
H6KO. A conditional allele was generated by Flp recombinase expres-
sion to remove the reporter gene. Cre recombinase expression under
the control of the Acta1 promoter excised exon 3 coding the catalytic
domain of the conditional H6PD allele in skeletal muscle. To generate
H6MKO, floxed homozygous H6KO mice on a C57BL/6 background
were crossed with Acta1‐Cre transgenic mice (C57BL/6 background,
ZIELINSKA ET AL. 271targeting Cre expression to skeletal muscle and heart). This generated
mice devoid of H6PDH activity in skeletal muscle cells. Genotyping
PCR was carried out on ear clip DNA by using the following gene spe-
cific primers (5′‐3′) Ef4685‐TTTGCACGGGCCTCAGGGTGG,
L3r4688‐TGGCTTTGGGAGGGAGTGGCCC, CreF‐GTAGTTATTCG
GATCATCAGCTACAC, and CreR‐GCTGCCACGACCAAGTGACAG
CAATG. The Ef4685 and L3r4688 primers were used to confirm suc-
cessful deletion of exon 3, which inactivated H6PD function (747 bp),
whereas the CreF/R primers confirmed gene knockout specific to skel-
etal muscle (402 bp).
2.5 | Western blot analysis
Twenty μg of protein isolated from quadriceps muscle or cells was run
on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis.
After electrophoresis, proteins were transferred onto immobilon
polyvinyl difluoride membranes (Millipore, Bedford, MA) at 100 V for
1 hour, in a buffer containing 25 mM Tris, 200 mM glycine, and 20%
(v/v) methanol. The membrane was blocked in phosphate‐buffered
saline (PBS) containing 0.1% (v/v) Tween 20 (PBS‐T) and 5% (w/v)
skimmed milk powder, washed, and then incubated with 11β‐HSD1
(in‐house) or H6PDH (Santa Cruz Biotechnology, Heidelberg, Germany)
rabbit polyclonal antibody, diluted 1/1000 overnight at 4°C in PBS‐T.
The membrane was then washed and incubated with goat antirabbit
secondary antibody diluted 1/25,000 in PBS‐T. Detection was
enhanced by chemiluminescence (Amersham Biosciences, Bucks, UK).
α‐Tubulin antibody (Santa Cruz Biotechnology, Heidelberg, Germany)
was used as a loading control.
2.6 | 11β‐Hydroxysteroid dehydrogenase type 1
activity assay
Tissue explants (~20 mg), 100 μg of muscle microsomes, confluent pri-
mary myofibroblasts, or differentiated myotubes were incubated with
100 nM 11‐DHC and 60,000 cpm 3H‐11‐DHC. Steroid incubation
was carried out for 4 hours for muscle tissue explants, microsomes,
and primary cells, while 30 minutes for liver. Subsequently, steroids
were extracted by using dichloromethane, separated by using a mobile
phase consisting of chloroform/absolute ethanol (92:8) by thin layer
chromatography, and scanned by using a Bioscan 200 imaging scanner
(LabLogic, Sheffield, UK). Corticosterone and 11‐DHC were purchased
from Sigma‐Aldrich (Poole, UK). 3H‐Corticosterone (specific activity
1 mCi/mL) was purchased from Amersham Biosciences (Amersham,
UK). 3H 11‐Dehydrocorticosterone was synthesized “in house” from
3H‐corticosterone.
2.7 | RNA analysis and real‐time polymerase chain
reaction
Tissue explants were homogenized with a PowerGen 125 homoge-
nizer (Fisher Scientific, Loughborough, UK). RNA was extracted by
using TriReagent (Sigma, Poole, UK) according to the manufacturer's
protocol. RNA quality was assessed by 1% agarose gel electrophoresis
and quantified spectrophotometrically. Two‐step RT‐PCR was per-
formed by using 1 μg of RNA, random hexamers, and Multiscribe
Reverse Transcriptase kit (Life Technologies, Cheshire, UK). Real‐timePCR was carried out as previously described.17 Gene expression was
assessed by using prevalidated specific TaqMan gene expression
assays and Universal PCR Master Mix (Life Technologies). Expression
levels were normalized to the housekeeping 18S gene. Data are
expressed as arbitrary units by using the following transformation:
expression = 1000 × [2−Δct]. Fold change in the expression was
calculated by using 2−ΔΔCt, where ΔCt = (Ct value of gene of
interest) − (Ct value of 18S). Data are expressed as fold change with
respect to WT animals.2.8 | Hexose‐6‐phosphate dehydrogenase activity
Hexose‐6‐phosphate dehydrogenase enzyme activity was measured
by spectrophotometric detection of NADPH upon the addition of
10 mM NADP+ and 10 mM G6P to 100 μg of skeletal muscle micro-
somes in a total volume of 300 μL using the Ultrospec 2100pro spec-
trophotometer (Amersham Biosciences). Microsomes were
permeabilized at 4°C with 0.5% Triton X‐100 for 30 minutes to allow
the free access of the cofactor to the intraluminal enzyme and incu-
bated in 20 mMMOP buffer (100 mM KCl, 20 mMNaCl, 1 mMMgCl2,
and pH 7.2) at 37°C. Absorbance readings were taken at 340 nm at
20 second intervals for 3 minutes.2.9 | Histological analysis
Quadriceps muscle was harvested from mice and then fixed in 10%
neutral buffered formalin. Each muscle from both null and WT mice
(n = 3 for each genotype) was paraffin embedded and cut into 5 μm
sections to be stained by haematoxylin and eosin and by periodic
acid‐Schiff according to the manufacturer's protocol for detection of
glycogen and to provide histological analysis of muscle structure.2.10 | Statistical analysis
Statistical comparisons were performed by using Prism 4 (GraphPad,
CA). Data are presented as mean ± SEM with statistical significance
defined as P less than .05. Where data were normally distributed,
unpaired Student t tests were used to compare single treatments to
control, while one‐way ANOVA on ranks was used to compare multi-
ple treatments or times by using SigmaStat 3.1 (Systat Software, CA,
USA). To perform statistical analysis on real‐time PCR data, mean
values of delta Ct were used.3 | RESULTS
3.1 | 11β‐Hydroxysteroid dehydrogenase type 1
expression and activity increases during muscle cell
differentiation
To explore potential for co‐regulation of 11β‐HSD1/H6PDH/G6PT in
muscle, we differentiated C2C12 muscle cells for 8 days, confirming
appropriate differentiation according to the upregulated expression of
the muscle‐specific markers α‐actin (P < .05) and myogenin (P < .001;
Figure 1A and B). We confirmed previous findings that 11β‐HSD1
mRNA significantly increased during differentiation (P < .001;
FIGURE 1 Expression of 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1), hexose‐6‐phosphate dehydrogenase (H6PDH), and glucose‐6‐
phosphate transporter (G6PT) in differentiating C2C12 cells
The anticipated mRNA expression profile of A, α‐actin and B, myogenin during muscle cell myotube differentiation. C, 11β‐HSD1 and D, H6PDH
mRNA expression with E, corresponding protein expression, F, 11β‐HSD1 oxo‐reductase activity, and G, G6PT mRNA expression across
differentiation (n = 3 in triplicate, *P < .05; **P < .01; ***P < .001 versus day 0 myoblasts)
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HSD1 protein (Figure 1E) and oxo‐reductase activity during differentia-
tion (P < .01; Figure 1F). Given the steady increase in 11β‐HSD1mRNA
over differentiation, we measured H6PDH and G6PT mRNA as part of
the axis determining 11β‐HSD1 enzyme activity. Hexose‐6‐phosphate
dehydrogenase expression was only marginally elevated after 8 days
(P < .05) not acquiring the same degree of upregulation as 11β‐HSD1
(Figure 1D and E), while there was no significant change in the
expression of G6PT (Figure 1G).3.2 | Glucocorticoid regulation of 11β‐
hydroxysteroid dehydrogenase type 1 and hexose‐6‐
phosphate dehydrogenase
Besides locomotion, skeletal muscle functions as the body's main stor-
age depot of insulin‐stimulated glucose uptake; therefore, we assessed
the 11β‐HSD1/H6PDH/G6PT triad's response to insulin and
glucocorticoid exposure. Treatment with synthetic glucocorticoid
DEX significantly increased 11β‐HSD1 mRNA expression (P < .01).
ZIELINSKA ET AL. 273Insulin had no effect and, in combination with DEX, did not oppose
increased 11β‐HSD1 expression (P < .05). Treatment with the gluco-
corticoid receptor antagonist Ru38486 prevented DEX‐mediated
11β‐HSD1 upregulation (P < .05; Figure 2A). We confirmed that the
increased levels of 11β‐HSD1 mRNA were functionally relevant by
showing increased reductase activity in cells exposed to increasing
concentrations of the endogenous glucocorticoid corticosterone
(Figure 2B). Regulation of H6PDH mRNA expression showed a similar
profile to 11β‐HSD1, being elevated in response to DEX (P < .05) and
DEX combined with insulin (P < .05; Figure 2C). Glucose‐6‐phosphate
transporter mRNA did not deviate from control levels with any
treatments (Figure 2D). Thus, glucocorticoid can positively regulate
11B‐HSD1 and H6PDH expression and result in increased 11β‐HSD1
activity in differentiated myotubes.3.3 | Muscle‐specific deletion of 1β‐hydroxysteroid
dehydrogenase type 1
To investigate the muscle‐specific roles of 11β‐HSD1 in the context of
whole body metabolic homeostasis and in response to glucocorticoid
excess, we developedmuscle‐specific HSD1MKOmice. The generation
and utilization ofHSD11B1 floxed mice have been previously described
and used extensively to investigate global, hepatocyte, and adipocyteFIGURE 2 Expression and regulation of 11β‐hydroxysteroid dehydrogena
and glucose‐6‐phosphate transporter (G6PT) in C2C12 myotubes
Following 24 hour treatment with dexamethasone (DEX; 1 μM) with or with
(1 μM) with or without DEX and Ru38486 (A) 11β‐HSD1 mRNA (B) correspo
(C) H6PDH mRNA is also responsive to DEX, while (D) G6PT is unresponsi
versus control or relevant treatment)loss of function.14,16-18 Initially, we evaluated the MEF2c‐Cre trans-
genic, but this did not result in Cre expression and failed to reveal
recombination of the floxed HSD11B1 locus or effects on 11β‐HSD1
activity, and as such, this line was abandoned. We then evaluated 2
additional Cre lines against the floxed HSD11B1 allele‐MCK‐Cre and
ACTA1‐Cre. Both transgenics expressed Cre and resulted in high level
recombination of the floxed HSD11B1 to a null allele. As MCK‐Cre
and ACTA‐Cre generated identical effects on 11β‐HSD1, for clarity,
we present the data associated with ACTA1‐Cre‐ HSD11B1 cross.
Mice homozygous for floxed HSD11B1 alleles were crossed with
mice heterozygous for a floxed allele and hemizygous for the Acta1‐
Cre transgene expressing Cre recombinase under the control of Acta1
(alpha actin) promoter (Figure 3A). Recombination between LoxP sites
(removal of exon 5) generated KO alleles restricted to skeletal muscle
as assessed in quadriceps, soleus, and tibialis anterior (TA). All other
tissues assessed—including liver, lung, kidney, and heart (although it
expresses Acta1 gene)—remained normal for conditional floxed exon
5 HSD11B1 alleles (Figure 3B). We next assessed levels of 11β‐
HSD1 mRNA by real‐time PCR by using primers and probes posi-
tioned to detect cDNA sequences corresponding to exon 5 in liver,
heart, lung, kidney, quadriceps, soleus, and TA tissues. Levels in
HSD1MKO tissues were compared with the same tissue collected
from control mice (negative for the Cre transgene; Figure 3C). Whilese type 1 (11β‐HSD1), hexose‐6‐phosphate dehydrogenase (H6PDH),
out glucocorticoid receptor (GR) antagonist Ru38486 (5 μM) or insulin
nding oxo‐reductase in response to increasing doses of corticosterone.
ve to all conditions (n = 3 in triplicate, *P < .05; ** P < .01; *** P < .001
FIGURE 3 Strategy and evaluation of muscle‐specific 11β‐HSD1 knockout (HSD1MKO)
A, Targeting strategy for HSD1MKO generation. Exon 5 of the conditional HSD11B1 allele is flanked with LoxP sites and bred with the muscle‐
specific Acta1‐Cre mice to generate HSD1MKO knockout allele mice. B, Polymerase chain reaction (PCR) detection of Cre positivity and a
knockout allele only in muscle tissues, validating the HSD1MKO model. The PCR products were derived from HSD1 primer sets on genomic DNA
isolated from a range of muscle and nonmuscle tissues. C, 11β‐Hydroxysteroid dehydrogenase type 1 (11β‐HSD1) mRNA expression measured in
tissue from HSD1MKO and wild‐type (WT) mice, with WT levels set at 1 across tissues. D, 11β‐HSD1 oxo‐reductase activity in muscle‐derived
microsomes, with or without 10 mMG6P, from HSD1MKO andWTmice. E, 11β‐HSD1mRNA expression and F, 11β‐HSD1 oxo‐reductase activity
in primary myoblasts derived from HSD1MKO andWTmice. G, Immunoblot of 11β‐HSD1 protein in HSD1MKO andWT quadriceps muscle (n = 6/
group *P < .05, **P < .01, ***P < .001 versus WT; Quad, quadriceps; TA, tibialis anterior)
274 ZIELINSKA ET AL.there were clear reductions in mRNA expression in muscle tissues (30‐
40%), they were not commensurate with the levels anticipated given
the degree of genomic recombination. Indeed, in liver and adipocyte
11β‐HSD1KO mice, the same level of genomic recombination seen
here was then mirrored by near complete loss of mRNA and enzyme
activity.14,16,18 To further examine this model, the oxo‐reductase activ-
ity of 11β‐HSD1 in the SRwasmeasured in intact microsomes prepared
from skeletal muscles. 11β‐Hydroxysteroid dehydrogenase type 1reductase activity was 3‐fold stimulated in microsomes preincubated
with 10 mMG6PT as previously shown.10 However, there was a similar
level of induction of activity in muscle microsomes from HSD1MKO,
corroborating the mRNA data (Figure 3D). 11β‐Hydroxysteroid dehy-
drogenase type 1 expression and activity were also measured in pri-
mary cultured WT and HSD1MKO myotubes (Figure 3E and F). Again,
although there was a decrement in the level of mRNA in HSD1MKO
myotubes, there was no difference between HSD1MKO and WT cells
ZIELINSKA ET AL. 275in the ability to reduce 11‐DHC to corticosterone (Figure 3E and F).
Finally, we immunoblotted for 11β‐HSD1 protein in lysates of quadri-
ceps from control and HSD1MKO mice and showed that protein levels
were similar in all animals tested, irrespective of genotype (Figure 3G).
Thus, while the HSD1MKOmodel was technically successful in achiev-
ing high level, muscle‐restricted, recombination of the HSD11B1 condi-
tional allele to a KO allele, it appears insufficient to impair 11β‐HSD1
protein expression or enzyme activity.3.4 | Muscle‐specific deletion of hexose‐6‐
phosphate dehydrogenase
To allow investigation of the muscle‐specific roles of H6PDH in the
context of whole body metabolic homeostasis, we have developed
muscle‐specific H6MKO mice. Mice homozygous for a conditional
floxed exon 3 H6PD allele were crossed with mice heterozygous for
a floxed allele and hemizygote for the Acta1‐Cre transgene
(Figure 4A). Initial characterization of H6MKO mice by using genomic
DNA isolated from a range of tissues showed that recombination of
the conditional allele to the KO allele is skeletal muscle‐specific (quad-
riceps and TA), with other tissues (including liver and kidney) remaining
unaltered (Figure 4B). Hexose‐6‐phosphate dehydrogenase mRNA
was assessed in the quadriceps and TA muscles of control and
H6MKO mice by real‐time PCR and reduced by approximately 75%
in the H6MKO compared with WT mice (Figure 4C). Hexose‐6‐phos-
phate dehydrogenase protein was almost undetectable when assessed
by immunoblot of lysates prepared from quadriceps of H6MKO and
control mice (Figure 4D). Using microsomes prepared form quadriceps,
we also show almost no ability to generate NADPH from NADP+ in
the H6MKO mice by using a H6PDH‐specific assay (Figure 4E). Previ-
ously, we have shown that 11β‐HSD1 activity in muscle explants of
global H6PDHKO mice changes from a reductase to a dehydroge-
nase.10,19 We measured these 11β‐HSD1 activities in quadriceps mus-
cle of H6MKO and show a significant loss of oxo‐reductase activity,
with a nonsignificant change in dehydrogenase activity, largely
endorsing the anticipated 11β‐HSD1 biochemistry (Figure 4F). Muscle
of H6PDHKO mice displays a type IIb fibre vacuolated myopathy and
elevated glycogen storage.19 We assessed the histological features of
control and H6MKO quadriceps by haematoxylin and eosin and
periodic acid‐Schiff staining for glycogen content (Figure 4G). This anal-
ysis again corroborated themuscle architecture and increased glycogen
storage consistent with a loss of muscle H6PDH activity (Figure 4G).
Finally, profiling of muscle from global H6PDHKO mice revealed a
distinct pattern of metabolic genes dysregulated in their expression
and coordinate activation of genes of the ER stress and unfolded pro-
tein responses.19 We measured a number of these signature genes in
H6MKO quadriceps, TA, and soleus and show H6MKO muscle to mir-
ror global H6PDHKO, here illustrated by reduced AMPD1 (most
downregulated metabolic gene) and increased HSPa5 (ER stress sen-
sor) and DDIT3 (ER stress effector) in H6MKO compared with controls
(Figure 4H). As previously seen, the effects on soleus in ER stress
response are minimal or absent (ie, HSPa5). Thus, unlike the
HSD1MKO mice, we show that H6PDH was significantly reduced in
skeletal muscle, leading to a muscle‐specific phenocopy of the myopa-
thy found previously in global H6PDHKO mice.4 | DISCUSSION
Intracellular glucocorticoid generation in skeletal muscle relies on the
coordinate expression of the proteins G6PT/H6PDH/11β‐HSD1. Hex-
ose‐6‐phosphate dehydrogenase and G6PT expressions are fairly con-
stant during postmuscle cell differentiation, suggesting that their levels
are sufficient to facilitate maintenance of appropriate SR redox condi-
tions, whereas 11β‐HSD1 expression and activity increase over differ-
entiation and are further responsive to exogenous glucocorticoids.
11β‐Hydroxysteroid dehydrogenase type 1 expression is regu-
lated by a plethora of hormones and cytokines, acting to increase or
decrease the ability of target cells to generate glucocorticoid.5 Gluco-
corticoids are known to increase the expression and activity of 11β‐
HSD1, which may be an important physiological mechanism to locally
increase available glucocorticoid and restrain the acute inflammatory
process, a response potentially perturbed in disease.20,21 We show
here that glucocorticoid signalling increases the expression of 11β‐
HSD1 and H6PDH, but not G6PT in muscle. In the context of endog-
enous or exogenous glucocorticoid excess, upregulation of 11β‐HSD1
in muscle may represent an unwanted “side‐effect” exacerbating
myopathy.3,16 In support of this, 11β‐HSD1KO mice do not display
detectable defects in muscle physiology indicating that 11β‐HSD1 is
dispensable for differentiation and more critical to modulating muscle
tissue responses to glucocorticoid. However, 11β‐HSD1KO mice are
protected from the adverse metabolic effects of glucocorticoid excess,
with muscle being particularly resistant.16 Thus, we have established
that regulation of 11β‐HSD1 expression, more so than H6PDH or
G6PT, appears a robust mechanism of altering intracellular capacity
to regenerate glucocorticoid and mechanistically linked to propagating
the deleterious effect of glucocorticoid excess in muscle.3,16
We propose that muscle 11β‐HSD1 expression can modify global
metabolic phenotype in response to elevated GC availability and is
therefore a legitimate therapeutic target tissue in the context of dis-
ease, and selective 11β‐HSD1 inhibitors are a promising therapy to
limit the side‐effects associated with GC excess. Furthermore, it has
been shown that expression and activity of 11β‐HSD1 are elevated
in skeletal muscle of diabetic individuals and pharmacological inhibition
of 11β‐HSD1 is insulin sensitizing.12,22
To assess these notions in more detail, we established 11β‐HSD1
and H6PDH muscle‐specific KO models, in which we would be able to
examine global and tissue‐specific phenotypes in the context of meta-
bolic disease such as glucocorticoid excess. Although we successfully
generated HSD1MKO mice with high‐level genomic recombination at
the HSD11B1 locus, to our surprise, robust 11β‐HSD1 activity was
present in skeletal muscle tissues. This was in contrast to highly effi-
cient knockout of 11β‐HSD1 activity restricted to liver and adi-
pose.14,16 Although the reason for this result is not entirely clear, we
can propose a likely scenario for these observations.
ACTA1‐Cre‐mediated recombination is never 100% efficient in any tis-
sue or cell type, and in the case of Acta‐Cre, up to 10% of alleles
remain unrecombined, essentially retaining the potential for WT gene
expression.23 Muscle is a multinucleate cell‐type, and therefore,
unrecombined HSD11B1 alleles could produce sufficient mRNA and
protein to retain almost control levels of 11β‐HSD1 reductase activity,
hence an inability to measure meaningful differences. We propose
FIGURE 4 Strategy and evaluation of hexose‐6‐phosphate dehydrogenase (H6MKO)
A, Targeting strategy for H6MKO generation. Exon 3 of a conditional allele (purchased from the European Conditional Mouse Mutagenesis
Program consortium) flanked with LoxP sites and bred with the muscle‐specific Acta1‐Cre mice to generate H6MKO knockout allele mice. B,
Polymerase chain reaction (PCR) detection of Cre positivity and a knockout H6PD allele only in muscle tissues, validating the H6MKO model. The
PCR products were derived from H6PD primer sets on genomic DNA isolated from muscle and nonmuscle tissues. C, Real‐time PCR analysis of
relative H6PDHmRNA expression in tissues from H6MKOmice. D, Immunoblot analysis of H6PDH protein expression in quadriceps from H6MKO
mice. E, Generation of NADPH from NADP by H6PDH in microsomes isolated from H6MKOmuscle. F, 11β‐Hydroxysteroid dehydrogenase type 1
(11β‐HSD1) oxo‐reductase activity and corresponding dehydrogenase activity in quadriceps muscle explants from wild type (WT) and H6MKO
mice. G, Histological analysis by haematoxylin and eosin (H&E) and periodic acid Schiff (PAS) staining (for glycogen content) in WT and H6MKO
quadriceps tissue. H, AMPD1 and ER stress markers DDIT3 and HSPa5 mRNA expression in quadriceps, TA, and soleus muscle from WT and
H6MKO mice (n = 6/group *P < .05, **P < .01, ***P < 0.001 versus WT; Quad, quadriceps; TA, tibialis anterior)
276 ZIELINSKA ET AL.that, in a stable system and at any one time, the rate of functional 11β‐
HSD1 accumulated from unrecombined alleles is greater than the rate
of clearance through proteasomal degradation, and so the tissue can
essentially retain WT levels of activity. In support of this, previousreports have suggested a long protein half‐life for 11β‐HSD1 leading
to persistence of protein, and thus enzyme activity, in a range of cell
types and models using similar genetic knockout or knockdown strate-
gies.24-26 However, this remains to be formally tested in the context of
ZIELINSKA ET AL. 277HSD1MKOmice. Similarly, we have not gone on to test HSD1MKOmice
against glucocorticoid excess. It may be that the unrecombined alleles are
unable to achieve the levels of 11β‐HSD1 induction that would be seen in
WT mice; hence, there would be reduced intracellular glucocorticoid
regenerative capacity and a protective effect would emerge.
We and others have previously shown that global H6PDH defi-
ciency causes metabolic defects associated with changes to 11β‐
HSD1‐mediated glucocorticoid metabolism in tissues such as liver
and adipose tissue. However, myopathy seen in global H6PDH defi-
ciency is glucocorticoid and 11β‐HSD1 independent, but it was
unknown whether loss of H6PDH in nonskeletal muscle tissue contrib-
uted to myopathy.17 Having now generated and validated H6MKO
mice, we can confirm phenocopy of the myopathy seen in global
H6PD KO mice and conclude that the phenotype originates in muscle
and is not influenced by other tissues. It would appear that, unlike
HSD1MKO mice, H6PDH is a locus more susceptible to complete
recombination, substantially reducing protein levels insufficient to sup-
port 11β‐HSD1 activity. This model will be useful for understanding
how skeletal muscle‐specific metabolic perturbation due to H6PDH
SR loss affects global metabolic homeostasis and as a model to evalu-
ate muscle specific responses to glucocorticoid excess.
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